Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model

International Immunopharmacology

Volumn 17, Issue 1, 2013, Pages 9-17

  Wang, Yu Qian ^a   Zhang, Hai Hong ^a   Liu, Chen Lu ^a   Wu, Hui ^a   Wang, Peng ^a   Xia, Qiu ^a   Zhang, Li Xing ^a   Li, Bo ^a   Wu, Jia Xin ^a   Yu, Bin ^a   Gu, Tie Jun ^a   Yu, Xiang Hui ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

DDA MPL; Melanoma; Oxaliplatin; Prime boost; Survivin

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; OXALIPLATIN; SURVIVIN; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84878733369     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.04.015     Document Type: Article

References (42)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21. (Pubitemid 27353455)
2. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
3. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008;99:1709-14.
4. Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 2011;60:99-109.
5. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 2008;57:1827-35.
6. Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 2011;102:1181-7.
7. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008;31:771-80.
8. Park JS, Kim HS, Park HM, Kim CH, Kim TG. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine 2011;29:8642-8.
9. Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ, Park JS, et al. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpGoligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 2008;99: 1034-9.
10. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14:461-6. (Pubitemid 36367426)
11. Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004;27:124-35. (Pubitemid 38282732)
12. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10-5. (Pubitemid 41606034)
13. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002;20(Suppl. 3):S34-9.
14. Nicholls EF, Madera L, Hancock RE. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci 2010;1213:46-61.
15. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007;121:216-26. (Pubitemid 46663090)
16. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun 2012;80:1510-8.
17. Kolibab K, Parra M, Yang AL, Perera LP, Derrick SC, Morris SL. A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine 2009;28:317-22.
18. Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 2012;61:1857-67.
19. Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araujo AF, Machado AV, et al. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 2011;79:2120-30.
20. Luo J, Zheng D, ZhangW, Fang F,Wang H, Sun Y, et al. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol J 2012;9:286.
21. Dai MS, Vassaux G, Xu M, You RI, Hsieh YF, Ouisse LH, et al. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. Vaccine 2012;30:6903-11.
22. Radaelli A, De Giuli Morghen C, Zanotto C, Pacchioni S, Bissa M, Franconi R, et al. A prime/boost strategy byDNA/fowlpox recombinants expressing amutant E7 protein for the immunotherapy of HPV-associated cancers. Virus Res 2012;170:44-52.
23. Harari A, Bart PA, StohrW, Tapia G, GarciaM,Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77. (Pubitemid 351185716)
24. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190:702-6. (Pubitemid 39049999)
25. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondinrelated adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006;74:5933-42. (Pubitemid 44484581)
26. Magalhaes I, Sizemore DR, Ahmed RK, Mueller S,Wehlin L, Scanga C, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 2008;3:e3790.
27. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51.
28. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
29. Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, et al. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 2011;29:5611-22.
30. Tang Y, Akbulut H, Maynard J, Petersen L, Fang X, Zhang WW, et al. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J Immunol 2006;177:5697-707. (Pubitemid 44527646)
31. Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells. Gene Ther 2010;17:1333-40.
32. Zhang H, Zhang S, Zhao D, Shi H, Yu Y, Wu Y, et al. Construction and expression of human survivin and preparation of its polyclonal antibody. Chem Res Chin Univ 2008;24:767-70.
33. You Q, Jiang C, Wu Y, Yu X, Chen Y, Zhang X, et al. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol 2012;75:77-84.
34. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, et al. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 2010;59:81-92.
35. Kobayashi J, Torigoe T, Hirohashi Y, Idenoue S, Miyazaki A, Yamaguchi A, et al. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. J Transl Med 2009;7:1.
36. Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009;58: 1801-7.
37. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009;21:346-51.
38. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15. (Pubitemid 39273730)
39. Celis E. Getting peptide vaccines to work: just a matter of quality control? J Clin Invest 2002;110:1765-8. (Pubitemid 36076482)
40. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE, et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999;73:10245-53.
41. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007;8:2-3. (Pubitemid 44943085)
42. McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol 2011;33:353-67.